FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098835966> ?p ?o ?g. }

• W2098835966 endingPage "1199" @default.
• W2098835966 startingPage "1192" @default.
• W2098835966 abstract "Background Etanercept, a soluble tumour necrosis factor receptor, lessens the severity of psoriasis as measured by physician-reported clinical outcomes. Equally important is the patient perspective on the effect of etanercept therapy on daily life. Objectives To assess patient-reported outcomes (PROs) in patients with psoriasis receiving etanercept therapy. Methods In this multinational, randomized, phase III trial, patients with psoriasis received placebo (n = 193), etanercept 50 mg per week (n = 196) or etanercept 50 mg twice weekly (n = 194) during the initial 12-week, double-blind period. Thereafter, all patients received open-label etanercept (50 mg per week). The following PROs were assessed: Dermatology Life Quality Index (DLQI), Short Form-36 Health Survey (SF-36), patient rating of pruritus, and patient global assessment of psoriasis. Results At week 12, DLQI total score improved by 65–70% in patients receiving etanercept compared with 6% in patients receiving placebo (P < 0·0001), and improvement in DLQI was clinically meaningful (≥ 5-point improvement or 0 score) for 72–77% of patients receiving etanercept therapy. All DLQI and SF-36 subscales and the SF-36 physical and mental component summary scores demonstrated significantly greater improvement with etanercept therapy than with placebo, illustrating that etanercept benefits patients with psoriasis across multiple domains that contribute to health-related quality of life. With etanercept therapy, distributions of patient ratings of pruritus and global assessment of disease shifted from moderate to severe (baseline) to minimal to good (week 12). Etanercept-induced benefits of PROs were maintained for patients who reduced their dose after 12 weeks. Conclusions Etanercept therapy improves PROs in patients with psoriasis and makes a meaningful difference to their lives. These results support the efficacy profile of physician-reported clinical measures while providing a more complete understanding of the benefits experienced by patients with psoriasis treated with etanercept." @default.
• W2098835966 created "2016-06-24" @default.
• W2098835966 creator A5006054781 @default.
• W2098835966 creator A5008906753 @default.
• W2098835966 creator A5061849637 @default.
• W2098835966 creator A5063001450 @default.
• W2098835966 creator A5072015843 @default.
• W2098835966 creator A5078821076 @default.
• W2098835966 creator A5082914214 @default.
• W2098835966 date "2005-12-01" @default.
• W2098835966 modified "2023-09-26" @default.
• W2098835966 title "Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial" @default.
• W2098835966 cites W1983185705 @default.
• W2098835966 cites W2008223306 @default.
• W2098835966 cites W2012581664 @default.
• W2098835966 cites W2019320114 @default.
• W2098835966 cites W2034585843 @default.
• W2098835966 cites W2067327580 @default.
• W2098835966 cites W2096991001 @default.
• W2098835966 cites W2112031699 @default.
• W2098835966 cites W2130086931 @default.
• W2098835966 cites W2139140379 @default.
• W2098835966 cites W2146843653 @default.
• W2098835966 cites W2161895264 @default.
• W2098835966 doi "https://doi.org/10.1111/j.1365-2133.2005.06948.x" @default.
• W2098835966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16307657" @default.
• W2098835966 hasPublicationYear "2005" @default.
• W2098835966 type Work @default.
• W2098835966 sameAs 2098835966 @default.
• W2098835966 citedByCount "122" @default.
• W2098835966 countsByYear W20988359662012 @default.
• W2098835966 countsByYear W20988359662013 @default.
• W2098835966 countsByYear W20988359662014 @default.
• W2098835966 countsByYear W20988359662015 @default.
• W2098835966 countsByYear W20988359662016 @default.
• W2098835966 countsByYear W20988359662017 @default.
• W2098835966 countsByYear W20988359662018 @default.
• W2098835966 countsByYear W20988359662019 @default.
• W2098835966 countsByYear W20988359662020 @default.
• W2098835966 countsByYear W20988359662021 @default.
• W2098835966 countsByYear W20988359662022 @default.
• W2098835966 countsByYear W20988359662023 @default.
• W2098835966 crossrefType "journal-article" @default.
• W2098835966 hasAuthorship W2098835966A5006054781 @default.
• W2098835966 hasAuthorship W2098835966A5008906753 @default.
• W2098835966 hasAuthorship W2098835966A5061849637 @default.
• W2098835966 hasAuthorship W2098835966A5063001450 @default.
• W2098835966 hasAuthorship W2098835966A5072015843 @default.
• W2098835966 hasAuthorship W2098835966A5078821076 @default.
• W2098835966 hasAuthorship W2098835966A5082914214 @default.
• W2098835966 hasConcept C126322002 @default.
• W2098835966 hasConcept C141071460 @default.
• W2098835966 hasConcept C142724271 @default.
• W2098835966 hasConcept C159110408 @default.
• W2098835966 hasConcept C16005928 @default.
• W2098835966 hasConcept C168563851 @default.
• W2098835966 hasConcept C17991360 @default.
• W2098835966 hasConcept C1862650 @default.
• W2098835966 hasConcept C204787440 @default.
• W2098835966 hasConcept C27081682 @default.
• W2098835966 hasConcept C2776173921 @default.
• W2098835966 hasConcept C2777011040 @default.
• W2098835966 hasConcept C2777226972 @default.
• W2098835966 hasConcept C2779951463 @default.
• W2098835966 hasConcept C2780564577 @default.
• W2098835966 hasConcept C71924100 @default.
• W2098835966 hasConceptScore W2098835966C126322002 @default.
• W2098835966 hasConceptScore W2098835966C141071460 @default.
• W2098835966 hasConceptScore W2098835966C142724271 @default.
• W2098835966 hasConceptScore W2098835966C159110408 @default.
• W2098835966 hasConceptScore W2098835966C16005928 @default.
• W2098835966 hasConceptScore W2098835966C168563851 @default.
• W2098835966 hasConceptScore W2098835966C17991360 @default.
• W2098835966 hasConceptScore W2098835966C1862650 @default.
• W2098835966 hasConceptScore W2098835966C204787440 @default.
• W2098835966 hasConceptScore W2098835966C27081682 @default.
• W2098835966 hasConceptScore W2098835966C2776173921 @default.
• W2098835966 hasConceptScore W2098835966C2777011040 @default.
• W2098835966 hasConceptScore W2098835966C2777226972 @default.
• W2098835966 hasConceptScore W2098835966C2779951463 @default.
• W2098835966 hasConceptScore W2098835966C2780564577 @default.
• W2098835966 hasConceptScore W2098835966C71924100 @default.
• W2098835966 hasIssue "6" @default.
• W2098835966 hasLocation W20988359661 @default.
• W2098835966 hasLocation W20988359662 @default.
• W2098835966 hasOpenAccess W2098835966 @default.
• W2098835966 hasPrimaryLocation W20988359661 @default.
• W2098835966 hasRelatedWork W1964984224 @default.
• W2098835966 hasRelatedWork W1978428707 @default.
• W2098835966 hasRelatedWork W2152281374 @default.
• W2098835966 hasRelatedWork W2155073280 @default.
• W2098835966 hasRelatedWork W2461170543 @default.
• W2098835966 hasRelatedWork W2744392461 @default.
• W2098835966 hasRelatedWork W2998923669 @default.
• W2098835966 hasRelatedWork W4238516826 @default.
• W2098835966 hasRelatedWork W4247679967 @default.
• W2098835966 hasRelatedWork W4321997075 @default.
• W2098835966 hasVolume "153" @default.

• next